Keywords
Biomateriales
Pseudomonas aeruginosa
How to Cite
Abstract
La Fibrosis Quística Pulmonar (FQP) es una enfermedad que se caracteriza por la producción excesiva de moco, el cual suele obstruir y dificultar el proceso respiratorio. Lo anterior crea un nicho propicio para el desarrollo de infecciones bacterianas, que junto con la respuesta inflamatoria provoca una pérdida progresiva de la función pulmonar. Aunque la antibioticoterapia es el tratamiento recomendado para la FQP, la acción bactericida de estos compuestos se ve limitada debido a la matriz moco-biopelícula generada por el hospedero y el patógeno, respectivamente. Si a lo anterior se le suma la resistencia de las bacterias a los antibióticos, nos encontramos con una suma de factores que no abonan en la recuperación de los pacientes con FQP. Por lo anterior, el presente artículo aborda la situación de la FQP y algunas perspectivas sobre los posibles tratamientos basados en el uso de biomateriales, con propiedades mucolíticas (alginato) y mucoadhesivas (quitosano), como matriz de soporte, transporte y liberación de bacteriófagos viables-específicos contra Pseudomonas aeruginosa.
References
Abdallah S. Abdelsattar, Fatma Abdelrahman, Alyaa Dawoud, Ian F. Connerton, and Ayman El-Shibiny. 2019. Encapsulation of E. coli phage ZCEC5 in chitosan–alginate beads as a delivery system in phage therapy. AMB Express 9, 1 (June 2019), 87. https://doi.org/10.1186/s13568-019-0810-9
AMFQ. 2017. Sobre Fibrosis Quística. Retrieved from http://fibrosisquistica.org.mx/~h4u3f3d9/sobre-la-enfermedad/
Dorothy H. Andersen. 1938. Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathologic study. American Journal of Diseases of Children 56, 2 (August 1938), 344–399. https://doi.org/10.1001/archpedi.1938.01980140114013
Mohamed E.I. Badawy, Entsar I. Rabea, Tina M. Rogge, Christian V. Stevens, Walter Steurbaut, Monica Höfte, and Guy Smagghe. 2005. Fungicidal and Insecticidal Activity of O-Acyl Chitosan Derivatives. Polym. Bull. 54, 4 (July 2005), 279–289. https://doi.org/10.1007/s00289-005-0396-z
Diana Bilton, Tacjana Pressler, Isabelle Fajac, John Paul Clancy, Dorota Sands, Predrag Minic, Marco Cipolli, Ivanka Galeva, Amparo Solé, Alexandra L. Quittner, Keith Liu, John P. McGinnis, Gina Eagle, Renu Gupta, Michael W. Konstan, Sabine Renner, Christiane Knoop, Anne Malfroot, Lieven Dupont, Kristine Desager, Frans De Baets, Miroslava Bosheva, Vania Nedkova, Ivan Galabov, Ivanka Galeva, Andreas Freitag, Nancy Morrison, Pearce Wilcox, Tanja Pressler, Yves Martinet, Raphael Chiron, Isabelle Fajac, Stephan Dominique, Philippe Reix, Anne Prevotat, Isabelle Sermet, Isabelle Durieu, Rainald Fischer, Rudolf Huber, Doris Staab, Uwe Mellies, Wolfgang Sextro, Tobias Welte, Heinrike Wilkens, Urte Sommerwerk, Burkhard Bewig, Ilias Inglezos, Stavros-Eleftherios Doudounakis, Olga Bede, Ferenc Gönczi, Rita Újhelyi, Edward McKone, Paul McNally, Vincenzina Lucidi, Marco Cipolli, Mario La Rosa, Laura Minicucci, Rita Padoan, Giovanna Pisi, Rolando Gagliardini, Carla Colombo, Inez Bronsveld, Ewa Sapiejka, Henryk Mazurek, Dorota Sands, Grażyna Górnicka, Iwona Stelmach, Halina Batura-Gabryel, Marta Rachel, Predrag Minic, Jaroslava Orosova, Branko Takac, Anna Feketova, Carmen Martinez, Gloria Garcia Hernandez, Jose Ramon Villa-Asensi, Silvia Gartner, Amparo Sole, Anders Lindblad, Martin Ledson, Diana Bilton, Joanna Whitehouse, Alan Smyth, Ian Ketchell, Timothy Lee, and Gordon MacGregor. 2020. Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis. Journal of Cystic Fibrosis 19, 2 (2020), 284–291. https://doi.org/10.1016/j.jcf.2019.08.001
Katie Bodner, Arin L. Melkonian, and Markus W. Covert. 2021. The Enemy of My Enemy: New Insights Regarding Bacteriophage–Mammalian Cell Interactions. Trends in Microbiology 29, 6 (June 2021), 528–541. https://doi.org/10.1016/j.tim.2020.10.014
Kathirvel Brindhadevi, Felix LewisOscar, Eleftherios Mylonakis, Sabarathinam Shanmugam, Tikendra Nath Verma, and Arivalagan Pugazhendhi. 2020. Biofilm and Quorum sensing mediated pathogenicity in Pseudomonas aeruginosa. Process Biochemistry 96, (September 2020), 49–57. https://doi.org/10.1016/j.procbio.2020.06.001
Alan S. Brody. 2004. Early morphologic changes in the lungs of asymptomatic infants and young children with cystic fibrosis. The Journal of Pediatrics 144, 2 (February 2004), 145–146. https://doi.org/10.1016/j.jpeds.2003.11.008
Rachel Yoon Kyung Chang, Theerthankar Das, Jim Manos, Elizabeth Kutter, Sandra Morales, and Hak-Kim Chan. 2019. Bacteriophage PEV20 and Ciprofloxacin Combination Treatment Enhances Removal of Pseudomonas aeruginosa Biofilm Isolated from Cystic Fibrosis and Wound Patients. AAPS J 21, 3 (April 2019), 49. https://doi.org/10.1208/s12248-019-0315-0
Rachel Yoon Kyung Chang, Theerthankar Das, Jim Manos, Elizabeth Kutter, Sandra Morales, and Hak-Kim Chan. 2019. Bacteriophage PEV20 and Ciprofloxacin Combination Treatment Enhances Removal of Pseudomonas aeruginosa Biofilm Isolated from Cystic Fibrosis and Wound Patients. AAPS J 21, 3 (May 2019), 49. https://doi.org/10.1208/s12248-019-0315-0
Michael E. Chirgwin, Margaret R. Dedloff, Alina Maria Holban, and Monica C. Gestal. 2019. Novel Therapeutic Strategies Applied to Pseudomonas aeruginosa Infections in Cystic Fibrosis. Materials 12, 24 (January 2019), 4093. https://doi.org/10.3390/ma12244093
Joan Colom, Mary Cano-Sarabia, Jennifer Otero, Javier Aríñez-Soriano, Pilar Cortés, Daniel Maspoch, and Montserrat Llagostera. 2017. Microencapsulation with alginate/CaCO3: A strategy for improved phage therapy. Sci Rep 7, 1 (January 2017), 41441. https://doi.org/10.1038/srep41441
Kris De Boeck, Matijn Weren, Marijka Proesmans, and Eitan Kerem. 2005. Pancreatitis Among Patients With Cystic Fibrosis: Correlation With Pancreatic Status and Genotype. Pediatrics 115, 4 (April 2005), e463–e469. https://doi.org/10.1542/peds.2004-1764
Jill Deacon, Sharif M. Abdelghany, Derek J. Quinn, Daniela Schmid, Julianne Megaw, Ryan F. Donnelly, David S. Jones, Adrien Kissenpfennig, J. Stuart Elborn, Brendan F. Gilmore, Clifford C. Taggart, and Christopher J. Scott. 2015. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: Formulation, characterisation and functionalisation with dornase alfa (DNase). Journal of Controlled Release 198, (January 2015), 55–61. https://doi.org/10.1016/j.jconrel.2014.11.022
Claire Edmondson and Jane C. Davies. 2016. Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implications. Therapeutic Advances in Chronic Disease 7, 3 (May 2016), 170–183. https://doi.org/10.1177/2040622316641352
Julia Emerson, Margaret Rosenfeld, Sharon McNamara, Bonnie Ramsey, and Ronald L. Gibson. 2002. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatric Pulmonology 34, 2 (2002), 91–100. https://doi.org/10.1002/ppul.10127
Katherine B. Frayman, David S. Armstrong, Rosemary Carzino, Thomas W. Ferkol, Keith Grimwood, Gregory A. Storch, Shu Mei Teo, Kristine M. Wylie, and Sarath C. Ranganathan. 2017. The lower airway microbiota in early cystic fibrosis lung disease: a longitudinal analysis. Thorax 72, 12 (December 2017), 1104–1112. https://doi.org/10.1136/thoraxjnl-2016-209279
Laura de Castro e Garcia, Lucas Montiel Petry, Pedro Augusto Van Der Sand Germani, Luiza Fernandes Xavier, Paula Barros de Barros, Amanda da Silva Meneses, Laura Menestrino Prestes, Luana Braga Bittencourt, Marina Puerari Pieta, Frederico Friedrich, and Leonardo Araújo Pinto. 2022. Translational Research in Cystic Fibrosis: From Bench to Beside. Front. Pediatr. 10, (May 2022), 881470. https://doi.org/10.3389/fped.2022.881470
Anthony M. George, Peter M. Jones, and Peter G. Middleton. 2009. Cystic fibrosis infections: treatment strategies and prospects. FEMS Microbiology Letters 300, 2 (November 2009), 153–164. https://doi.org/10.1111/j.1574-6968.2009.01704.x
Vinod Ghodake, Jyoti Vishwakarma, Sirisha L. Vavilala, and Vandana Patravale. 2020. Cefoperazone sodium liposomal formulation to mitigate P. aeruginosa biofilm in cystic fibrosis infection: A QbD approach. International Journal of Pharmaceutics 587, (2020), 119696. https://doi.org/10.1016/j.ijpharm.2020.119696
Azucena Gonzalez Gomez and Zeinab Hosseinidoust. 2020. Liposomes for Antibiotic Encapsulation and Delivery. ACS Infect. Dis. 6, 5 (May 2020), 896–908. https://doi.org/10.1021/acsinfecdis.9b00357
Oussama Hallouch, John Marinos, Florence Thibault, Kim-Nhien Vu, Jean Chalaoui, Patrick Bourgouin, Laurence Péloquin, Véronique Freire, François Tremblay, and Carl Chartrand-Lefebvre. 2022. Cystic fibrosis in the 21st century: what every radiologist should know. Clinical Imaging 84, (April 2022), 118–129. https://doi.org/10.1016/j.clinimag.2022.02.004
Freya Harrison. 2007. Microbial ecology of the cystic fibrosis lung. Microbiology 153, 4 (2007), 917–923. https://doi.org/10.1099/mic.0.2006/004077-0
Marcus Hill, Matthew Twigg, Emer A. Sheridan, John G. Hardy, J. Stuart Elborn, Clifford C. Taggart, Christopher J. Scott, and Marie E. Migaud. 2019. Alginate/Chitosan Particle-Based Drug Delivery Systems for Pulmonary Applications. Pharmaceutics 11, 8 (August 2019), 379. https://doi.org/10.3390/pharmaceutics11080379
Sami Hraiech, Fabienne Brégeon, and Jean-Marc Rolain. 2015. Bacteriophage-based therapy in cystic fibrosis-associated Pseudomonas aeruginosa infections: rationale and current status. Drug Design, Development and Therapy 9, (July 2015), 3653–3663. https://doi.org/10.2147/DDDT.S53123
Margaret O. Ilomuanya, Nkechi V. Enwuru, Emmanuella Adenokun, Abigail Fatunmbi, Adebowale Adeluola, and Cecilia I. Igwilo. 2022. Chitosan-Based Microparticle Encapsulated Acinetobacter baumannii Phage Cocktail in Hydrogel Matrix for the Management of Multidrug Resistant Chronic Wound Infection. Turk J Pharm Sci 19, 2 (April 2022), 187–195. https://doi.org/10.4274/tjps.galenos.2021.72547
Irene Jurado-Martín, Maite Sainz-Mejías, and Siobhán McClean. 2021. Pseudomonas aeruginosa: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors. International Journal of Molecular Sciences 22, 6 (January 2021), 3128. https://doi.org/10.3390/ijms22063128
Sandeep Kaur, Anila Kumari, Anjana Kumari Negi, Vikas Galav, Shikha Thakur, Manish Agrawal, and Vandana Sharma. 2021. Nanotechnology Based Approaches in Phage Therapy: Overcoming the Pharmacological Barriers. Frontiers in Pharmacology 12, (2021). Retrieved February 13, 2024, from https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.699054
You-Seok Kim, Qiang Li, Hwa-Young Youn, and Dae Young Kim. 2019. Oral Administration of Chitosan Attenuates Bleomycin-induced Pulmonary Fibrosis in Rats. In Vivo 33, 5 (September 2019), 1455–1461. https://doi.org/10.21873/invivo.11624
A. Katharina Kolonko, Janes Efing, Yadira González-Espinosa, Nadine Bangel-Ruland, Willy van Driessche, Francisco M. Goycoolea, and Wolf-Michael Weber. 2020. Capsaicin-Loaded Chitosan Nanocapsules for wtCFTR-mRNA Delivery to a Cystic Fibrosis Cell Line. Biomedicines 8, 9 (September 2020), 364. https://doi.org/10.3390/biomedicines8090364
Silke van Koningsbruggen-Rietschel, Jane C. Davies, Tacjana Pressler, Rainald Fischer, Gordon MacGregor, Scott H. Donaldson, Knut Smerud, Nils Meland, Jann Mortensen, Marie Ø. Fosbøl, Damian G. Downey, Astrid H. Myrset, Hugo Flaten, and Philip D. Rye. 2020. Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomised, double-blind, placebo-controlled, crossover phase 2b study. ERJ Open Research 6, 4 (October 2020). https://doi.org/10.1183/23120541.00132-2020
Jaya Lakkakula, Arpita Roy, Karan Krishnamoorthy, Saad Alghamdi, Mazen Almehmadi, Pratik Gujarathi, Prachi Pansare, Mamdouh Allahyani, Osama Abdulaziz, Kamini Velhal, Most Chand Sultana Khatun, and Md Jamal Hossain. 2022. Alginate-Based Nanosystems for Therapeutic Applications. Journal of Nanomaterials 2022, (September 2022), e6182815. https://doi.org/10.1155/2022/6182815
Danielle E. Large, Rudolf G. Abdelmessih, Elizabeth A. Fink, and Debra T. Auguste. 2021. Liposome composition in drug delivery design, synthesis, characterization, and clinical application. Advanced Drug Delivery Reviews 176, (2021), 113851. https://doi.org/10.1016/j.addr.2021.113851
Yu Lin, Diana Quan, Rachel Yoon Kyung Chang, Michael Y.T. Chow, Yuncheng Wang, Mengyu Li, Sandra Morales, Warwick J. Britton, Elizabeth Kutter, Jian Li, and Hak-Kim Chan. 2021. Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation—A proof-of-principle study in a P. aeruginosa lung infection model. European Journal of Pharmaceutics and Biopharmaceutics 158, (January 2021), 166–171. https://doi.org/10.1016/j.ejpb.2020.11.019
Jim Manos. 2021. Current and Emerging Therapies to Combat Cystic Fibrosis Lung Infections. Microorganisms 9, 9 (September 2021), 1874. https://doi.org/10.3390/microorganisms9091874
Kelly A. Mason and Alan D. Rogol. 2022. Trends in Growth and Maturation in Children with Cystic Fibrosis Throughout Nine Decades. Front. Endocrinol. 13, (July 2022), 935354. https://doi.org/10.3389/fendo.2022.935354
Kelly A. Mason and Alan D. Rogol. 2022. Trends in Growth and Maturation in Children with Cystic Fibrosis Throughout Nine Decades. Front. Endocrinol. 13, (July 2022), 935354. https://doi.org/10.3389/fendo.2022.935354
María Moreno-Sastre, Marta Pastor, Amaia Esquisabel, Eulàlia Sans, Miguel Viñas, Aarne Fleischer, Esther Palomino, Daniel Bachiller, and José Luis Pedraz. 2016. Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis. International Journal of Pharmaceutics 498, 1 (2016), 263–273. https://doi.org/10.1016/j.ijpharm.2015.12.028
National Guideline Alliance (UK). 2017. Cystic Fibrosis: Diagnosis and management. National Institute for Health and Care Excellence (NICE), London. Retrieved December 30, 2023, from http://www.ncbi.nlm.nih.gov/books/NBK464183/
Renee N. Ng, Anna S. Tai, Barbara J. Chang, Stephen M. Stick, and Anthony Kicic. 2021. Overcoming Challenges to Make Bacteriophage Therapy Standard Clinical Treatment Practice for Cystic Fibrosis. Frontiers in Microbiology 11, (2021). Retrieved January 15, 2024, from https://www.frontiersin.org/articles/10.3389/fmicb.2020.593988
Manoel Ortiz, Denise Soledade Jornada, Adriana Raffin Pohlmann, and Sílvia Stanisçuaski Guterres. 2015. Development of Novel Chitosan Microcapsules for Pulmonary Delivery of Dapsone: Characterization, Aerosol Performance, and In Vivo Toxicity Evaluation. AAPS PharmSciTech 16, 5 (October 2015), 1033–1040. https://doi.org/10.1208/s12249-015-0283-3
Krishna Kumar Patel, Muktanand Tripathi, Nidhi Pandey, Ashish Kumar Agrawal, Shilpkala Gade, Md Meraj Anjum, Ragini Tilak, and Sanjay Singh. 2019. Alginate lyase immobilized chitosan nanoparticles of ciprofloxacin for the improved antimicrobial activity against the biofilm associated mucoid P. aeruginosa infection in cystic fibrosis. International Journal of Pharmaceutics 563, (2019), 30–42. https://doi.org/10.1016/j.ijpharm.2019.03.051
Ewelina Piktel, Urszula Wnorowska, Joanna Depciuch, Dawid Łysik, Mateusz Cieśluk, Krzysztof Fiedoruk, Joanna Mystkowska, Magdalena Parlińska-Wojtan, Paul A. Janmey, and Robert Bucki. 2022. N-Acetyl-Cysteine Increases Activity of Peanut-Shaped Gold Nanoparticles Against Biofilms Formed by Clinical Strains of Pseudomonas aeruginosa Isolated from Sputum of Cystic Fibrosis Patients. Infect Drug Resist 15, (March 2022), 851–871. https://doi.org/10.2147/IDR.S348357
Paul M. Quinton. 1999. Physiological Basis of Cystic Fibrosis: A Historical Perspective. Physiological Reviews 79, 1 (January 1999), S3–S22. https://doi.org/10.1152/physrev.1999.79.1.S3
Golnar Rahimzadeh, Majid Saeedi, Mahmood Moosazadeh, Seyyed Mohammad Hassan Hashemi, Amirhossein Babaei, Mohammad Sadegh Rezai, Kosar Kamel, Kofi Asare-Addo, and Ali Nokhodchi. 2021. Encapsulation of bacteriophage cocktail into chitosan for the treatment of bacterial diarrhea. Sci Rep 11, 1 (August 2021), 15603. https://doi.org/10.1038/s41598-021-95132-1
Raha Ahmad Raus, Wan Mohd Fazli Wan Nawawi, and Ricca Rahman Nasaruddin. 2021. Alginate and alginate composites for biomedical applications. Asian Journal of Pharmaceutical Sciences 16, 3 (2021), 280–306. https://doi.org/10.1016/j.ajps.2020.10.001
Nicole Reyne, Alexandra McCarron, Patricia Cmielewski, David Parsons, and Martin Donnelley. 2023. To bead or not to bead: A review of Pseudomonas aeruginosa lung infection models for cystic fibrosis. Frontiers in Physiology 14, (2023). Retrieved January 30, 2024, from https://www.frontiersin.org/articles/10.3389/fphys.2023.1104856
S. G. Rotman, V. Post, A. L. Foster, R. Lavigne, J. Wagemans, A. Trampuz, M. Gonzalez Moreno, W.-J. Metsemakers, D. W. Grijpma, R. G. Richards, D. Eglin, and T. F. Moriarty. 2023. Alginate chitosan microbeads and thermos-responsive hyaluronic acid hydrogel for phage delivery. Journal of Drug Delivery Science and Technology 79, (January 2023), 103991. https://doi.org/10.1016/j.jddst.2022.103991
Don B. Sanders, Zhanhai Li, Anita Laxova, Michael J. Rock, Hara Levy, Jannette Collins, Claude Ferec, and Philip M. Farrell. 2014. Risk Factors for the Progression of Cystic Fibrosis Lung Disease throughout Childhood. Annals ATS 11, 1 (January 2014), 63–72. https://doi.org/10.1513/AnnalsATS.201309-303OC
Secretaría de Salud. DETECCIÓN, DIAGNÓSTICO Y TRATAMIENTO INTEGRAL DE FIBROSIS QUÍSTICA. gob.mx. Retrieved August 26, 2022, from http://www.gob.mx/salud|cnegsr/documentos/deteccion-diagnostico-y-tratamiento-integral-de-fibrosis-quistica
Michal Shteinberg, Iram J. Haq, Deepika Polineni, and Jane C. Davies. 2021. Cystic fibrosis. Lancet 397, 10290 (June 2021), 2195–2211. https://doi.org/10.1016/S0140-6736(20)32542-3
Michal Shteinberg, Iram J. Haq, Deepika Polineni, and Jane C. Davies. 2021. Cystic fibrosis. Lancet 397, 10290 (June 2021), 2195–2211. https://doi.org/10.1016/S0140-6736(20)32542-3
Michal Shteinberg, Iram J. Haq, Deepika Polineni, and Jane C. Davies. 2021. Cystic fibrosis. Lancet 397, 10290 (June 2021), 2195–2211. https://doi.org/10.1016/S0140-6736(20)32542-3
Kokkarachedu Varaprasad, Tippabattini Jayaramudu, Vimala Kanikireddy, Claudio Toro, and Emmanuel Rotimi Sadiku. 2020. Alginate-based composite materials for wound dressing application: A mini review. Carbohydrate Polymers 236, (2020), 116025. https://doi.org/10.1016/j.carbpol.2020.116025
Cecilia Velino, Francesca Carella, Alessio Adamiano, Maurizio Sanguinetti, Alberto Vitali, Daniele Catalucci, Francesca Bugli, and Michele Iafisco. 2019. Nanomedicine Approaches for the Pulmonary Treatment of Cystic Fibrosis. Frontiers in Bioengineering and Biotechnology 7, (2019). Retrieved August 26, 2022, from https://www.frontiersin.org/articles/10.3389/fbioe.2019.00406
Michael Wilschanski and Peter R. Durie. 2007. Patterns of GI disease in adulthood associated with mutations in the CFTR gene. Gut 56, 8 (August 2007), 1153–1163. https://doi.org/10.1136/gut.2004.062786
Thiago Medeiros Zacaron, Mariana Leite Simões e Silva, Mirsiane Pascoal Costa, Dominique Mesquita e Silva, Allana Carvalho Silva, Ana Carolina Morais Apolônio, Rodrigo Luiz Fabri, Frederico Pittella, Helvécio Vinícius Antunes Rocha, and Guilherme Diniz Tavares. 2023. Advancements in Chitosan-Based Nanoparticles for Pulmonary Drug Delivery. Polymers 15, 18 (January 2023), 3849. https://doi.org/10.3390/polym15183849
A. Zahoor, Sadhna Sharma, and G. K. Khuller. 2005. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. International Journal of Antimicrobial Agents 26, 4 (October 2005), 298–303. https://doi.org/10.1016/j.ijantimicag.2005.07.012
M. Gulrez Zariwala, Harshada Bendre, Anatoliy Markiv, Sebastien Farnaud, Derek Renshaw, Kevin M.G. Taylor, and Satyanarayana Somavarapu. 2018. Hydrophobically modified chitosan nanoliposomes for intestinal drug delivery. Int J Nanomedicine 13, (September 2018), 5837–5848. https://doi.org/10.2147/IJN.S166901
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2024 Materiales Avanzados